## **Primary Series Hospitalization/Severe Disease** mRNA ■ non-mRNA ■ Multiple Study Country Design VE (95% CI) Study End Date in 2021 С Bar-On et al. (5) 0.95 (0.92, 0.97) Israel Barda et al. (63) MC 0.93 (0.88, 0.97) Israel С 0.93 (0.85, 0.97) Muhsen et al. (69) Israel MC Sharma et al. (71) USA 0.45 (0.27, 0.58) С 0.69 (0.56, 0.78) Mattiuzzi and Lippi (37) Italy McConeghy et al. (57) (S1) USA С 0.82 (0.56, 0.94) С USA 0.46 (-0.16, 0.79)McConeghy et al. (57) (S2) USA MC 0.81 (0.80, 0.82) Mehta et al. (82) С USA Tartof et al. (19) 0.70 (0.48, 0.83) USA MC Butt et al. (20) 0.52 (0.46, 0.57) Hulme et al. (75) UK MC 0.80 (0.78, 0.82) Study End Date in 2022 Andersson et al. (17) Finland MC 0.96 (0.88, 1.00) **——** MC 0.88 (0.71, 1.00) Andersson et al. (17) Norway Andersson et al. (17) MC 0.90 (0.80, 1.00) Sweden Sweden MC 0.88 (0.81, 0.95) Andersson et al. (17) Ioannou et al. (41) USA MC $\vdash$ 0.53 (0.48, 0.58) Ng et al. (76) С Singapore 0.70 (0.49, 0.82) Kislaya et al. (32) (60-79yo) 0.21 (0.02, 0.36) Portugal С С Kislaya et al. (32) (80+yo) Portugal 0.16 (0.01, 0.28) Ridgway et al. (29) USA MCC $\vdash$ 0.59 (0.54, 0.63) USA MC Desai et al. (18) 0.44 (0.02, 0.68) MC 0.80 (0.56, 0.91) Chemaitelly et al. (78) Qatar -0.250.25 0.75 0 0.5 1 Vaccine Effectiveness (VE)

## Mortality

